Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 128Recruiting 57Active not recruiting 39Terminated 38Unknown 13Not yet recruiting 5Withdrawn 4Enrolling by invitation 1

Sponsor Class

OTHER 2INDUSTRY 2FED 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 1

Conditions

Prostatic Neoplasms 5Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Gemcitabine 13Radiotherapy 12Androgen Antagonists 12Specimen Handling 9Magnetic Resonance Spectroscopy 9pembrolizumab 8toripalimab 7darolutamide 7Nivolumab 7Drug Therapy 7Docetaxel 7Radiosurgery 6Cystectomy 6enzalutamide 5apalutamide 5abiraterone 5Mitomycin 5Cisplatin 5Abiraterone Acetate 5disitamab vedotin 4Pluvicto 4Cyclophosphamide 4Axitinib 4tislelizumab 3fludarabine 3enfortumab vedotin 3cemiplimab 3cabozantinib 3Sunitinib 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × enzalutamide × Genitourinary × Clear all
NCT07620574 2026-06-02

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Exelixis

Phase 3 Not yet recruiting
5,000 enrolled
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT07592910 2026-05-18

MOMENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07104110 2025-08-05

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT06430411 2024-05-28

OLIGOMET

Medical University of Vienna

Not yet recruiting
500 enrolled
Genitourinary

Prostatic Neoplasms

NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

James J. Peters Veterans Affairs Medical Center

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡